Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

ND4BB: addressing the antimicrobial resistance crisis

Nature Reviews Microbiology volume 12, pages 231–232 (2014)Cite this article

Subjects

The Innovative Medicines Initiative (IMI) recently launched its third public–private partnership, ENABLE (European Gram-negative Antibacterial Engine), to tackle the shortage of effective antimicrobial drugs for Gram-negative pathogens.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Boucher H. W. et al. Clin. Infect. Dis. 56, 1685–1694 (2013).

    Article  Google Scholar 

  2. Morel C. M. & Mossialos E. BMJ 340, c2115 (2010).

    Article  Google Scholar 

  3. Laxminarayan R. et al. Lancet Infect. Dis. 13, 1057–1098 (2013).

    Article  Google Scholar 

  4. Rex J. H. et al. Lancet Infect. Dis. 13, 269–275 (2013).

    Article  Google Scholar 

  5. Caliendo A. M. et al. Clin. Infect. Dis. 57, S139–S170 (2013).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Vice President and Head of Infection, Global Medicines Development, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, USA.,

    John H. Rex

Authors
  1. John H. Rex
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John H. Rex.

Ethics declarations

Competing interests

J.H.R. is an employee and shareholder of AstraZeneca Pharmaceuticals. He is a non-executive director of, shareholder of, and consultant to F2G Pharmaceuticals and a consultant to Advent Life Sciences (an investor in F2G Pharmaceuticals).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rex, J. ND4BB: addressing the antimicrobial resistance crisis. Nat Rev Microbiol 12, 231–232 (2014). https://doi.org/10.1038/nrmicro3245

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrmicro3245

This article is cited by

Search

Advanced search

Quick links

Nature Briefing Microbiology

Sign up for the Nature Briefing: Microbiology newsletter — what matters in microbiology research, free to your inbox weekly.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing: Microbiology